Liminatus Pharma
Wilmington
About Liminatus Pharma
Liminatus Pharma is a clinical-stage biopharmaceutical company that specializes in developing immune-modulating cancer therapies. Its pipeline includes a humanized anti-CD47 monoclonal antibody (IBA101) targeting advanced solid tumors, a Guanylyl Cyclase C (GCC) cancer vaccine in Phase II trials for gastrointestinal cancers, and a GCC-targeted CAR-T cell therapy. The company also holds exclusive rights to the YN1203 companion diagnostic for checkpoint inhibitor therapies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Total funding: $34.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2026)
- Ticker: nasdaq:LIMN
- Website: liminatuspharma.com
- Phone: [email protected]
Industries & Categories
Advice, Biopharma, Biotechnology, Health Care, Management Consulting
Social Profiles
Canonical: https://fsome.com/organization/liminatus-pharma-118940 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.